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The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) is a key gene expressed in EBV type III latent
infection that can transactivate numerous promoters, including those for all the other type III viral latency
genes as well as cellular genes responsible for cell proliferation. EBNA-2 is essential for EBV-mediated
immortalization of primary B lymphocytes. We now report that EBNA-2, a phosphoprotein, is hyperphospho-
rylated specifically in mitosis. Evidence that the cyclin-dependent kinase p34cdc2 may be involved in this
hyperphosphorylation includes (i) coimmunoprecipitation of EBNA-2 and p34cdc2, suggesting physical asso-
ciation; (ii) temporal correlation between hyperphosphorylation of EBNA-2 and an increase in p34cdc2 kinase
activity; and (iii) ability of purified p34cdc2/cyclin B1 kinase to phosphorylate EBNA-2 in vitro. Hyperphos-
phorylation of EBNA-2 appears to suppress its ability to transactivate the latent membrane protein 1 (LMP-1)
promoter by about 50%. The association between EBNA-2 and PU.1 is also decreased by about 50% in
M-phase-arrested cells, as shown by coimmunoprecipitation from cell lysates, suggesting that hyperphospho-
rylation of EBNA-2 impairs its affinity for PU.1. Finally, endogenous LMP-1 mRNA levels in M phase are
around 55% of those in asynchronously growing cells. These results suggest that regulation of gene expression
during type III latency may be regulated in a cell-cycle-related manner.
The biologic hallmark of Epstein-Barr virus (EBV) and its
interaction with B lymphocytes is latency. Gene expression in
latent EBV infection is strictly regulated in a stereotypic fash-
ion. Four types of latency, each having a distinct pattern of
gene expression, have been described. Type I latency is asso-
ciated with Burkitt’s lymphoma (BL) and BL cell lines; in this
form of latency, viral antigen expression is generally restricted
to EBV nuclear antigen 1 (EBNA-1) (13, 19). In immunocom-
petent persons, the EBV genome persists in a pool of resting
G0 B lymphocytes (5, 47) in which EBNA-1 transcripts and
protein are not detected, termed type 0 latency (47). Type II
latency is found in nasopharyngeal carcinoma and in Hodgkin’s
disease (9, 87). EBNA-1, latent membrane protein 1 (LMP-1),
LMP-2A, and LMP-2B are expressed in type II latency, which
can also be established in vitro by fusing lymphoblastoid cell
line cells with certain EBV-negative human epithelial, fibro-
blast, or hemopoietic cell lines (3, 32). Type III latency is
represented by lymphoblastoid cell lines established after EBV
infection of primary B cells in vitro and by group III BL lines
(33, 86). Nine viral proteins are expressed, including six nu-
clear proteins (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B,
EBNA-3C, and EBNA-LP) and the three integral membrane
proteins (LMP-1, LMP-2A, and LMP-2B) (reviewed in refer-
ences 7 and 9).
EBNA-2, a key gene expressed in type III latency, is a phos-
phoprotein (17, 18) that localizes to various compartments of
the nucleus, including the nucleoplasm, the chromatin fraction,
and the nuclear matrix (54, 58). EBNA-2 is essential for EBV
transformation, since EBV with a region including EBNA-2
deleted is unable to transform B lymphocytes (45). In addition,
EBNA-2 regulates promoters for both viral and cellular genes
that are important for transformation of B lymphocytes, in-
cluding LMP-1, which is the principal EBV oncoprotein (75,
76) and is also essential for transformation of B lymphocytes
and other cell types. EBNA-2 is the best-characterized viral
factor that transactivates the LMP-1 promoter (LMP-1p) (30,
62, 63, 74, 78). EBNA-LP, which is also a phosphoprotein, can
activate LMP-1p in cooperation with EBNA-2 (24, 52). In
addition to LMP-1, it is well established that EBNA-2 can
transactivate a number of other genes, including the cellular
CD21, CD23, bcl-2, and c-fgr and the EBV LMP-2A and
LMP-2B genes as well as the BamHI C promoter (Cp), which
gives rise to all the viral nuclear antigens, EBNA-1, -2, -3A,
-3B, -3C, and -LP (39, 63, 66). EBNA-2 transactivates Cp and
the other promoters through EBNA-2 response elements
within each promoter. EBNA-2 does not bind directly to DNA
but exerts its function by interacting with the cellular proteins
recombination signal-binding protein (RBP-J) (20, 26) and
PU.1 (30) and by recruiting TFIIB, TFIIH, TAF40, p100, and
p300/CBP via EBNA-2’s acidic activating domain (70–72, 79).
All EBNA-2-responsive promoters described to date have
DNA-binding sequences for RBP-J, while interaction be-
tween EBNA-2 and PU.1 is specific to the LMP-1 promoter,
which contains a binding sequence for PU.1 (30).
Although there is much information on how expression of
individual genes is regulated in EBV latent infection, the pos-
sibility that there is a general mechanism for regulating the
latency genes has received little attention. We have provided
evidence that in type I latency control of latent gene expression
is regulated by the cell cycle (4). Both EBNA-1 and a host
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factor, E2F, are involved in the transcriptional regulation of
Qp, from which EBNA-1, the only EBV nuclear antigen ex-
pressed in type I latency, is transcribed. EBNA-1 acts in an
autoregulatory manner to repress Qp transcription by binding
to sites in the Q locus located downstream of the Qp start site
(57, 68). However, in vitro, E2F can overcome EBNA-1-me-
diated repression of Qp in transient-transfection assays by
competing with and displacing EBNA-1 from the Q locus,
thereby activating Qp (67). Since E2F transcriptional activity is
cell cycle regulated with higher activity in the S phase, tran-
scription of endogenous EBNA-1 mRNA in vivo is regulated in
a cell-cycle-dependent manner, resulting in increased EBNA-1
mRNA levels in S phase (4).
In the more complex type III latency, during which all the
latency genes are expressed, whether or how they are regulated
in relation to the cell cycle is unexplored. The only report
germane to this idea is that the phosphorylation pattern of
EBNA-LP is regulated during the cell cycle, being hyperphos-
phorylated specifically in the G2/M phase (34). It has been
reported that the ability of EBNA-LP to induce LMP-1 ex-
pression cooperatively with EBNA-2 is regulated by phosphor-
ylation, that mutation of the major phosphorylation sites of
EBNA-LP reduce its coactivation ability (85), and that p34cdc2
kinase is involved in phosphorylation of this site in vitro (31).
However this study was carried out in asynchronously growing
cells, in which EBNA-LP is hypophosphorylated (34). Thus,
the effect of G2/M-phase-specific hyperphosphorylation on
EBNA-LP’s function remains unknown, leaving the question
of whether and how cell cycle might influence the function of
EBV latent genes in type III latency essentially unaddressed.
Since EBNA-LP by itself does not activate specific promoters
(24, 52), whereas EBNA-2 is the major transactivator for all
the other viral genes expressed in type III latency (35, 43, 63,
73, 78), we therefore chose EBNA-2 as a target for study
during the cell cycle.
In this paper we report that EBNA-2 is hyperphosphorylated
in a mitosis-specific manner and that this modification appears
to suppress the ability of the protein to transactivate the
LMP-1 promoter. We found also that the cyclin-dependent
kinase, p34cdc2, which is a master regulator of the G2-to-M
transition in eukaryotic cells (12, 41), is likely involved in
EBNA-2 hyperphosphorylation.
MATERIALS AND METHODS
Cell culture. HeLa cells were obtained from the American Type Culture and
grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum. The X50-7 cell line was derived from human cord blood lympho-
cytes immortalized in vitro by infection of B95-8 EBV; it expresses the genes for
EBNAs and LMPs (type III latency) (81). DG75 is an EBV-negative BL cell line
(2). The stable BJAB cell line expressing EBNA-2 was a gift from Fred Wang
(77). All these cell lines were maintained in RPMI 1640 plus 10% fetal bovine
serum.
Enrichment for mitotic cells. Cells were enriched for mitosis by treatment with
nocodazole for 12 to 18 h at a final concentration of 60 ng/ml for X50-7 cells and
DG75 cells and 250 ng/ml for HeLa cells. Both treated and untreated HeLa cells
in mitosis were collected by vigorous shaking off into the medium as described
earlier (69); the interphase cells remain attached. To arrest transfected cells in
mitosis, nocodazole was applied 20 h after transfection of HeLa cells (50) and 36
to 48 h after transfection of DG75. The mitotic index was determined by 4,6-
diamidino-2-phenylindole (DAPI) staining and microscopic examination (14,
11).
Propidium iodide staining and FACS analysis. To determine DNA content
and cell-cycle status at each time point, 2  106 cells from each fraction fixed in
70% ethanol were collected by centrifugation and washed once with 1 phos-
phate-buffered saline (PBS) solution and resuspended in PBS containing 0.1%
Triton X-100, 2 mg of RNase A/ml, and 50 mg of propidium iodine (Sigma)/ml.
Data were acquired on a Becton Dickinson FACSStarPlus and analyzed by use
of ModFit (Verity Software House). To sort cells in different phases, asynchro-
nously growing cells were labeled with 0.01 mM Hoechst 33342 (Sigma) at 37°C
for 45 min and sorted with a DAKO Cytomation fluorescence-activated cell
sorting (FACS) Moflo sorter. Cells within the G0/G1, S, or G2/M phases were
collected in sterile PBS at 4°C (56).
Plasmids. The LMP1 promoter construct pGL2 (512/72)-luciferase, which
has two tandem copies of the LMP1 512/72 promoter element, was provided
by Jeffery Lin and Elliott Kieff (37). The pBS-LMP1 plasmid for RNase protec-
tion assay (RPA) was provided by Paul Farrell (65). The -galactosidase (-Gal)
expression plasmid pCMV-Gal (6177-1) was purchased from Clontech. pSG5-
EBNA-2 contains the entire EBNA-2 open reading frame of EBV strain W91
under the control of the simian virus 40 (SV40) early promoter in the vector
pSG5 (Stratagene) and was provided by Elliott Kieff (37). The pGL2 promoter
construct, which contains the SV40 early promoter upstream of the luciferase
gene, was purchased from Promega.
In vitro transcription and translation. In vitro transcription and translation of
EBNA-2 was carried out in rabbit reticulocytes with the TNT system (Promega)
according to the manufacturer’s instructions with 1 g of plasmid pSG5-
EBNA-2.
Immunoprecipitation. Cells were washed once with PBS and then resus-
pended in lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5%
NP-40, 5 mM dithiothreitol, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride
[Complete; Roche]). After freezing and thawing three times, debris was removed
by centrifugation at 4°C for 15 min at 14,000  g. Protein concentration was
determined by the Bradford assay (Bio-Rad). Whole-cell lysates (1 mg) from
asynchronous and nocodazole-synchronized G2/M-phase X50-7 cells were first
incubated with 10 g of EBNA-2 antibody, p34cdc2 antibody, or normal mouse
immunoglobulin G (IgG) in 500 l of protein lysis buffer at 4°C for 1 h; immune
complexes were incubated with protein A/G-Sepharose beads (Santa Cruz) at
4°C overnight, washed four times with protein lysis buffer, and then eluted from
the protein G-Sepharose with 2 Laemmli’s buffer by boiling for 3 min. Dena-
tured immune complexes were separated by electrophoresis and analyzed by
immunoblotting.
Immunoblotting. Whole-cell lysates (100 g) were separated on sodium do-
decyl sulfate–10% polyacrylamide gel electrophoresis (SDS-PAGE) gels for de-
tection of PU.1, p34cdc2, and cyclin B1 and on 8% gels for detection of EBNA-2.
The proteins were then transferred to nitrocellulose membrane. Membranes
were blocked in 5% milk for 30 min at room temperature (RT), rinsed in
Tris-buffered saline with Tween (TBST) three times for 5 min, and then incu-
bated at RT for 1 h or overnight at 4°C with the following antibodies: EBNA-2
monoclonal antibody (PE2; 1:500; DAKO), LMP-1 antibody (CS1-4; 1:100;
DAKO), p34cdc2 monoclonal antibody (clone 17; 1:200; Santa Cruz), cyclin B1
monoclonal antibody (GNS-1; 1:250; BD Pharmingen), PU.1 polyclonal antibody
(D19; 1:100; Santa Cruz), -actin monoclonal antibody (AC-15; 1:5,000; Sigma),
and antitubulin monoclonal antibody (clone B7; 1:500; Santa Cruz). After rinsing
three times for 5 min in TBST, the membranes were incubated with appropriate
horseradish peroxidase-conjugated secondary antibodies (1:5,000; Amersham
Biosciences) for 1 h at RT and subsequently washed with TBST three times for
5 min. Specific signals were detected by using the Supersignal detection reagent
following the manufacturer’s instructions (Pierce) and exposed to Kodak XAR-5
film.
Phosphatase treatment. EBNA-2 immunoprecipitated from whole-cell lysates
(500 g) was treated for 1 h at 30°C with 2,000 U of lambda phosphatase (New
England Biolabs, Inc.). Samples were then diluted with 2 Laemmli’s buffer and
electrophoresed on an SDS–8% polyacrylamide gel. EBNA-2 was detected by
immunoblot analysis.
Kinase assay. A histone H1 kinase assay was carried out as described previ-
ously (34). Briefly, p34cdc2 and cyclin B1 were immunoprecipitated from whole-
cell lysates (500 g) at indicated time points with 10 g of monoclonal p34cdc2
and cyclin B1 antibodies. After washing three times with lysis buffer and once
with reaction buffer, the immunoprecipitate complex was collected and incu-
bated at 30°C in 50 l of kinase reaction mixture containing 50 mM Tris-HCl (pH
7.4), 10 mM MgCl2, 1 mM dithiothreitol, 10 M ATP, 5 Ci of [-32P]ATP
(6,000 Ci/mmol; Amersham), and 0.5 mg of histone H1/ml for 15 min. The
reaction was terminated by the addition of 10 l of 6 Laemmli’s sample buffer
and boiling for 5 min. The 32P-phosphorylated histone H1 was separated on 10%
polyacrylamide gels and analyzed on a PhosphorImager (Molecular Dynamics).
To assay EBNA-2 phosphorylation by purified p34cdc2/cyclin B1 kinase (New
England Biolabs), EBNA-2 was immunoprecipitated from in vitro-transcribed
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and -translated reticulocyte lysates or from whole-cell lysates (1 mg) of asyn-
chronously growing X50-7 cells with PE2 antibody. EBNA-2 phosphorylation
was carried out in a 25-l reaction mixture containing 50 mM Tris-HCl (pH 7.5),
10 mM MgCl2, 1 mM EGTA, 2 mM dithiothreitol, 0.01% Brij 35, 80 M ATP,
and 40 Ci of [-32P]ATP (6,000 Ci/mmol; Amersham) in the presence of 40 U
of purified p34cdc2/cyclin B1 kinase (New England Biolabs). After incubation for
30 min at 30°C, the immune complex was washed three times with kinase
reaction buffer. The reaction was terminated by the addition of 2 Laemmli’s
sample buffer. After boiling for 5 min, the samples were subjected to SDS–8%
PAGE. Proteins were transferred to a polyvinylidene difluoride membrane and
subjected to immunoblotting of EBNA-2 as described above. The 32P-incorpo-
rated EBNA-2 protein was analyzed by autoradiography.
Transfections. Approximately 106 log-phase DG75 cells were transfected in
0.4 ml of RPMI 1640–10% fetal bovine serum with a Bio-Rad Gene-Pulser at 220
V and 975 F. For reporter assays, each transfection mixture contained 10 g of
the LMP-1 promoter construct pGL2 (512/72)-luciferase plasmid, the indi-
cated amounts of EBNA-2 plasmid, and 1 g of pCMV-Gal to permit normal-
ization for transfection efficiency. Total plasmid DNA was made constant by the
addition of pSG5 vector DNA (Stratagene). In some circumstances, 10 g of
pGL2-promoter plasmid and 1 g of pCMV-Gal were cotransfected. After
transfection, cells were incubated in 10 ml of complete medium and subjected to
M-phase enrichment by nocodazole treatment as described above. HeLa cells
were transiently transfected with the use of FuGENE6 according to the manu-
facturer’s instructions.
Reporter assay. Sixty-six hours posttransfection, cells were rinsed in PBS and
lysed in reporter lysis buffer (Promega) with one freeze-thaw cycle. For luciferase
reporter assays, cell lysates (20 l each) were combined with luciferase assay
reagent (Promega), and the relative light units were measured in an Lmax
luminometer (Molecular Devices Corp.). -Gal assays were performed as de-
scribed elsewhere (15). -Gal values were used to normalize all results for
transfection efficiency. All reporter assay results are averages derived from three
independent repetitions done in triplicate.
RNA isolation and RPA. Total RNAs were isolated with a Qiagen RNeasy
mini kit. RPAs were performed with total RNA with the RNase protection kit II
(Ambion). The hybridization temperature was 37°C. The human glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) probe was supplied by U.S. Biochemi-
cals, Inc. The LMP-1 probe for RPA, which was from the pBS-LMP1 construct
and labeled with [	-32P]UTP by in vitro transcription, corresponds to nucleotides
169033 to 169423 in the B95-8 EBV genome (65). The protected fragments are
220 and 90 bp (65). The EBNA-2 probe was generated by PCR with the Extend
high-fidelity PCR system (Boehringer Mannheim) with pSG5-EBNA-2 as tem-
plate and specific primers. The sequence of primer A was 5-GCTCTAGATA
ATACGACTCACTATAGGGCGACAGACCCAAGCTTGGTACCGAGCTC
GGATCCGATGGAGGATACCAATCATCGG-3 and that of primer B was
5-GCTCTAGACTAAGTCCAGTCCTCGGTCTTC-3. Primer A contained
the T7 RNA polymerase promoter sequence to allow the transcription of the
antisense EBNA-2 RNA probe and a spacer to provide separation between the
unprotected and protected regions of the probe in the RPA. The protected
region of EBNA-2 corresponds to nucleotides 49656 to 49846 of the EBV B95-8
strain. The protected fragments are 190 bp. The purified PCR product was
confirmed by enzymatic digestion and used directly for RNA probe synthesis by
use of T7 RNA polymerase (Promega) and [32P]UTP (Amersham).
RESULTS
Mitosis-specific hyperphosphorylation of EBNA-2. To study
EBNA-2 expression during the cell cycle, X50-7 cells were
arrested by nocodazole, or asynchronously growing cells were
sorted in G0/G1, S, and G2/M phases by FACS (Fig. 1A, left
panel). In the sorted G2/M fraction, the mitotic index was 9%
(range, 8 to 10%) as determined by DAPI staining (11, 14)
(Fig. 1A, right panel), so most of the cells in this fraction were
in G2 phase, whereas in nocodazole-arrested cells more than
75% were in mitosis. Western blotting showed that the protein
level of EBNA-2 did not vary appreciably during the cell cycle.
However, in nocodazole-arrested cells (M), a component of
EBNA-2 migrated more slowly (Fig. 1A, right panel). This shift
was not detected in the FACS-analyzed cells in G2/M, in which
there were only 9% in mitosis. Similar slower electrophoretic
mobility of EBNA-2 was also detected in nocodazole-arrested
EBV-negative BJAB cells stably expressing EBNA-2 (77) (Fig.
1B).
The most likely explanation for the shift in migration de-
tected in the EBNA-2 protein is modification by phosphoryla-
tion. We therefore treated EBNA-2 immunoprecipitated from
asynchronously growing and nocodazole-arrested cells with 

phosphatase to remove any potential phosphates. Treatment
of EBNA-2 from nocodazole-arrested cells caused an increase
in mobility of EBNA-2 as detected by Western blotting (Fig.
1C); 
 phosphatase treatment also affected migration of
EBNA-2 obtained from asynchronous cells (Fig. 1C). This
result is consistent with an earlier report that EBNA-2 is phos-
phorylated in asynchronously growing cells and is dephospho-
rylated by calf intestinal alkaline phosphatase or potato acid
phosphatase in vitro (18). The results indicate, therefore, that
EBNA-2 is hyperphosphorylated in nocodazole-arrested cells.
Phospho-amino acid analysis of EBNA-2 disclosed that the
protein is phosphorylated on serine and threonine and not on
tyrosine residues in both hyper- and hypophosphorylated
forms of EBNA-2 (unpublished data).
Further, we wanted to establish whether EBNA-2 hyper-
phosphorylation observed in nocodazole-arrested cells re-
flected a mitosis-specific modification, since in cells in suspen-
sion it is physically impossible to separate the M phase from
G2. We therefore transfected EBNA-2 into HeLa cells and
separated cells in mitosis from other phases by vigorous shak-
ing (49, 53, 55, 69). As shown in Fig. 1D, hyperphosphorylation
of EBNA-2 was confined to mitotic cells obtained by shaking
off from the monolayer. Most importantly, EBNA-2 hyper-
phosphorylation was observed in mitotic cells collected by
shake-off from an asynchronously growing population of un-
treated HeLa cells. Above 90% of the shake-off fraction of
cells were in M phase, as determined by DAPI staining, and
hyperphosphorylation of EBNA-2 was confirmed by a 
 phos-
phatase assay (data not shown). Together these results indicate
that (i) EBNA-2 is subjected to mitosis-specific hyperphospho-
rylation, both during physiological mitotic division and during
mitotic arrest induced by a microtubule-targeting drug; (ii)
hyperphosphorylation of EBNA-2 does not require any other
EBV gene; and (iii) hyperphosphorylation of EBNA-2 is inde-
pendent of cell type. Thus, hyperphosphorylation of EBNA-2
is most likely regulated by a cellular kinase which is active in
the M phase of the cell cycle.
EBNA-2 physically associates with p34cdc2, and hyperphos-
phorylation of EBNA-2 coincides with the increase in p34cdc2/
cyclin B1 kinase activity. p34cdc2/cyclin B1 is the kinase com-
plex responsible for the G2-to-M transition, and it has maximal
activity in mitosis (55). Therefore, we asked whether EBNA-2
and p34cdc2 kinase are physically associated in type III latency.
Study of the physical association of EBNA-2 with p34cdc2 by
coimmunoprecipitation in X50-7 cells disclosed that EBNA-2
could be coimmunoprecipitated with p34cdc2 antibody in both
asynchronously growing and M-phase-arrested cells (Fig. 2A),
indicating that both hypophosphorylated and hyperphosphory-
lated EBNA-2 associates with p34cdc2. Thus, these results sug-
gest that EBNA-2 physically associates with p34cdc2 kinase.
Then we determined if M-specific hyperphosphorylation of
EBNA-2 correlates with p34cdc2/cyclin B1 kinase activity. As
shown in Fig. 2B, an increase of hyperphosphorylation of
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EBNA-2 temporally coincides with increased p34cdc2/cyclin B1
kinase activity, as evaluated by histone H1 kinase assay (40).
Role of p34cdc2 kinase in EBNA-2 phosphorylation. A num-
ber of proteins are subjected to mitosis-specific phosphoryla-
tion, which in most cases is involved with p34cdc2 kinase (22, 36,
40). To test whether the p34cdc2 kinase might be involved in
phosphorylation of EBNA-2, we carried out in vitro kinase
assays by using purified p34cdc2 kinase. EBNA-2 immunopre-
cipitated from in vitro-transcribed and -translated rabbit re-
ticulocyte lysates was first used as substrate to test whether
p34cdc2 kinase might phosphorylate EBNA-2 in vitro. As
shown in Fig. 3A, EBNA-2 can be phosphorylated efficiently by
addition of p34cdc2 kinase. Next we investigated whether en-
dogenous EBNA-2 could be phosphorylated by p34cdc2 kinase.
As shown in Fig. 3B, the endogenous EBNA-2 protein immu-
noprecipitated from asynchronously growing cells was weakly
FIG. 1. EBNA-2 is hyperphosphorylated specifically in mitosis. (A) Left top panel, X50-7 cells arrested by nocodazole (ND); left bottom panel,
G0/G1, S and G2/M phases sorted from asynchronously growing cells by FACS (brackets indicate collected fractions). Percentages in each phase
are indicated. Right panel, EBNA-2 protein analyzed by immunoblotting with PE2 antibody; tubulin was the loading control. The mitotic index
was determined by DAPI staining. (B) Immunoblots of EBNA-2 stably expressed in EBV-negative BJAB cells in nocodazole-arrested M phase
(M) or in asynchronous cells (Asy) in whole-cell lysates. (C) Hyperphosphorylation of EBNA-2 in nocodazole-arrested M-phase cells. Immuno-
precipitated EBNA-2 from M-phase and asynchronous cells was subjected to immunoblotting directly () or after treatment with 2,000 U of 

phosphatase (
PPase) (). (D) EBNA-2 is hyperphosphorylated in both nocodazole-arrested and untreated mitotic cells. HeLa cells were
transfected with EBNA-2 and treated with nocodazole (250 ng/ml) for 18 h, at 20 h after transfection, or were left untreated. M-phase cells were
separated from other phases by vigorous shaking. Immunoblots for EBNA-2 of extracts from mitotic cells collected by shake-off from nocodazole-
arrested (lane 1) and untreated (lane 3) cell monolayers and from cells remaining adherent (lanes 2 and 4) were analyzed.
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phosphorylated without the addition of p34cdc2 kinase, whereas
it was dramatically phosphorylated with the addition of the pu-
rified p34cdc2 kinase. A control Western analysis for EBNA-2
showed that essentially equal amounts of EBNA-2 protein
were used in the kinase assays (Fig. 3). These results suggest
that p34cdc2 kinase may be involved in EBNA-2 mitotic hyper-
phosphorylation, at least in part.
Transactivation of the LMP-1 promoter by EBNA-2 is de-
creased in M phase. We next turned to study functional con-
sequences of hyperphosphorylation of EBNA-2. EBNA-2 can
transactivate the LMP-1 promoter, as shown by cotransfection
with LMP-1 promoter reporter constructs (30, 63, 78). How-
ever, all such studies have been done in asynchronously grow-
ing cells, when EBNA-2 is hypophosphorylated. We therefore
compared transactivation of the LMP-1 promoter by EBNA-2
in asynchronous and M-phase-arrested cells to test whether
hyperphosphorylation of EBNA-2 might affect its functional
ability. EBNA-2 can transactivate the LMP-1 promoter in both
asynchronously growing and M-phase-arrested cells; however,
transactivation of the LMP-1 promoter by EBNA-2 in M phase
decreased by about 50% (P  0.01) (Fig. 4A). Western blotting
showed essentially equal amounts of EBNA-2 in the asynchro-
nous and M-phase cells as well as hyperphosphorylation of
EBNA-2 in M phase (Fig. 4C). Therefore, the decreased trans-
activation of the LMP-1 promoter by EBNA-2 in M phase is
related to hyperphosphorylation of EBNA-2, not to variation
in EBNA-2 expression level. To rule out a cell-cycle-indepen-
dent effect of nocodazole, we used an irrelevant promoter, the
SV40 early promoter, as a control and found that its activity
was not affected by nocodazole (Fig. 4B).
Association of EBNA-2 with PU.1 is decreased in M phase
when EBNA-2 is hyperphosphorylated. EBNA-2 transactivates
downstream promoters by interacting with the cellular se-
quence-specific DNA-binding proteins RBP-J/CBF-1 (20, 26)
and PU.1 (30); PU.1 is specific for the LMP-1 promoter (30).
To examine why there was decreased transactivation of the
LMP-1 promoter in the M phase, we compared the association
of EBNA-2 with PU.1 in asynchronously growing and M-
phase-arrested cells by coimmunoprecipitation. Glutathione
S-transferase (GST)–EBNA-2 fusion proteins can interact di-
FIG. 2. (A) Physical association of EBNA-2 with p34cdc2 kinase. Whole cell X50-7 lysates from asynchronous or nocodazole-arrested M-phase
cells (A and M, respectively) were immunoprecipitated with p34cdc2 antibody or normal mouse IgG; immune complexes were separated by
electrophoresis. EBNA-2 and p34cdc2 were detected by immunoblotting. (B) Temporal correlation between EBNA-2 hyperphosphorylation and
p34cdc2 kinase activity. X50-7 cells were continuously treated with nocodazole for the indicated times, and whole-cell lysates were separated by
electrophoresis and immunoblotted with EBNA-2 antibody (upper panel). For the kinase assay, p34cdc2/cyclin B1-kinase complex was immuno-
precipitated from the same cell lysates, and kinase activity was determined by [-32p]ATP incorporation into histone H1 (middle panel) and
measured with a PhosphorImager (lower panel).
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rectly with PU.1 in vitro; however, association of EBNA-2 with
PU.1 has not been detected in vivo (30). As shown in Fig. 5,
PU.1 can be coimmunoprecipitated by EBNA-2 antibody in
both asynchronous and M-phase X50-7 cells. Interestingly, we
consistently observed that less PU.1 was coimmunoprecipi-
tated by EBNA-2 in M phase, although the input protein level
of PU.1 was constant (Fig. 5). Thus, the association of EBNA-2
and PU.1 is decreased when EBNA-2 is hyperphosphorylated.
These data help to explain why LMP-1 promoter activity de-
creases in M-phase-arrested cells (Fig. 4A).
Decreased levels of endogenous LMP-1 mRNA and protein
in M phase. Finally, to determine whether the level of endog-
enous LMP-1 mRNA is associated with EBNA-2 hyperphos-
phorylation, we compared EBNA-2 and LMP-1 steady-state
mRNA levels in asynchronously growing and nocodazole-ar-
rested M-phase X50-7 cells by RPA. As shown in Fig. 6A and
FIG. 3. Involvement of p34cdc2 kinase in EBNA-2 phosphorylation. In vitro-transcribed-translated EBNA-2 from rabbit reticulocyte lysates
(A) or endogenous EBNA-2 from total lysates of asynchronously growing cells (B) were immunoprecipitated from cells and used as substrates for
kinase assays in the presence () or absence () of purified p34cdc2/cyclin B1 kinase. Immunoprecipitation with normal mouse IgG served as the
negative control. After resolving by electrophoresis and transfer onto membrane, phosphorylation of EBNA-2 was detected by autoradiography
(top panel). Equal levels of EBNA-2 were confirmed by immunoblotting (bottom panel).
FIG. 4. Decreased transactivation of the LMP-1 promoter by EBNA-2 in M-phase-arrested cells. DG75 cells were transfected with reporter
plasmid p(512/72)LMP1p-luc in addition to 5 g of pSG5-EBNA-2 expression vector. After transfection, half the cells were arrested at M phase
by nocodazole (M); the other half served as the asynchronous control (Asy). Luciferase assays were performed to evaluate promoter activity. In
each phase, transactivation of the LMP-1 promoter by EBNA-2 was normalized to the vector control. (A) Comparison of transactivation of the
LMP-1 promoter by EBNA-2 in M-phase-arrested and asynchronous control cells. (B) Comparison of SV40 early promoter activity in G2/M-
arrested and asynchronous control cells. Each data point in panels A and B represents the average of three independent experiments done in
triplicate. Error bars represent the means  standard errors of the means. *, P  0.01. (C) Immunoblot of EBNA-2 with PE2 antibody in
asynchronously growing (Asy) and M-phase-arrested (M) cells in a representative experiment; tubulin was used as a loading control.
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B, in the M phase the LMP-1 steady-state level of mRNA was
around 50% of that detected in asynchronously growing cells,
which indicated a decreased abundance of LMP-1 mRNA,
whereas the EBNA-2 steady-state level of mRNA did not show
an obvious change. Also, the LMP-1 protein level decreased in
M phase (Fig. 6C). These results confirm in vivo the LMP-1
promoter reporter assay results and demonstrate that hyper-
phosphorylation of EBNA-2 correlates with decreased steady-
state levels of endogenous LMP-1 mRNA and protein in the M
phase of the cell cycle.
DISCUSSION
As a major gene in type III latency, EBNA-2’s function in
transactivation and transformation has been extensively ad-
dressed (30, 62, 63, 74, 78), and it is known to be a phospho-
protein (17, 18). However, modification of phosphorylation of
the protein during the cell cycle has not been reported. In this
work, we showed that EBNA-2 phosphorylation status is
clearly regulated during the cell cycle, being hyperphosphory-
lated specifically in mitosis, which suggests involvement of the
p34cdc2 kinase. Further, cell-cycle-related hyperphosphoryla-
tion of EBNA-2 appears to affect its function, resulting in
decreased transactivation of one of its responsive promoters,
LMP-1.
In addition to X50-7 cells, we detected the M-phase-specific
hyperphosphorylation of EBNA-2 in three other type III la-
tency cell lines (W91 [44], BL41-B95-8 [21], and CB0 B95-8 [a
gift of N. Raab-Traub]) (data not shown), indicating that the
mitosis-specific hyperphosphorylation of EBNA-2 is a general
phenomenon in type III latency. Since it can also be detected
in the EBV-negative cell lines BJAB, DG75, and even HeLa
cells expressing EBNA-2 stably or transiently (Fig. 1B and D
and 4C), the mitotic hyperphosphorylation of EBNA-2 is in-
dependent of any other EBV gene product and must be regu-
lated by a cellular kinase or kinases. We suggest a possible role for
p34cdc2/cyclin B1 kinase, which has its highest level of activity in
mitosis (55) and regulates the G2-to-M transition (51). Hyper-
phosphorylated EBNA-2 contains phosphoserines and phos-
phothreonines but no phosphotyrosine (unpublished results),
which indicates the involvement of a Ser/Thr kinase. Cyclin-
dependent kinase p34cdc2 (CDK1) is a Ser/Thr kinase (48), and
we have presented evidence that p34cdc2 kinase might be in-
volved in hyperphosphorylation of EBNA-2. First, both hypo-
and hyperphosphorylated EBNA-2 could be coimmunopre-
cipitated with p34cdc2 antibody (Fig. 2A), indicating physical
association with p34cdc2. An attempt to coimmunoprecipitate
p34cdc2 with EBNA-2 antibody (PE2 [86]) was unsuccessful,
perhaps because the binding site was masked by the PE2 an-
tibody. In fact, EBNA-2 has been reported to associate with a
cellular protein with a molecular mass of 32 kDa, which is
similar to that of p34cdc2 (34 kDa), by use of another EBNA-2
antibody (6, 7). Second, there was a temporal correlation be-
tween hyperphosphorylation of EBNA-2 and an increase in
p34cdc2/cyclin B1 kinase activity (Fig. 2B). Third, p34cdc2 kinase
could dramatically increase EBNA-2 phosphorylation in vitro
(Fig. 3). In mitosis, a number of proteins involved in transcrip-
tional regulation and some sequence-specific transcription fac-
tors (28, 36, 42, 59) are subjected to mitosis-specific phosphor-
ylation, which in most cases is performed by a mitotic protein
kinase, either p34cdc2 kinase and/or a kinase activated by it (25,
36). Whether other kinases may also be involved in hyperphos-
phorylation of EBNA-2 is unknown. The efficient phosphory-
lation of EBNA-2 in the presence of p34cdc2 kinase suggests
that p34cdc2 may well be involved in mitotic hyperphosphory-
lation of EBNA-2 directly or indirectly.
Actually, EBNA-2 is not the only viral gene product that is
associated with p34cdc2 and whose phosphorylation is involved
with p34cdc2. EBNA-LP was reported to be hyperphosphory-
lated in nocodazole-arrested X50-7 cells, and it can be phos-
phorylated by p34cdc2 kinase in vitro (31, 34). Also, both Ser-89
and Ser-219, the major adenovirus E1A phosphorylation sites,
have been phosphorylated in vitro by p34cdc2 purified from
HeLa cells (8). In another case, the herpes simplex virus type
1 protein product of UL42 can bind and be phosphorylated by
p34cdc2 kinase in vitro (1). Thus, there may be common mech-
anisms whereby the host cell regulates phosphorylation of viral
proteins. On the other hand, the association of viral proteins
with CDKs may influence the kinase function. The Tax onco-
protein of human T-cell leukemia virus type 1 (HTLV-1) in-
duces leukemia in transgenic mice and permanent T-cell
growth in vitro. Tax directly interacts with CDK4 in vitro and
in vivo. The Tax/CDK4 complex represents an active holoen-
zyme that phosphorylates the retinoblastoma (Rb) protein in
vitro; binding-deficient Tax mutants failed to activate CDK4
(23), indicating that direct association with Tax is required for
enhanced kinase activity. Tax also increased the association
of CDK4 with its positive cyclin regulatory subunit. The
EBNA-2–p34cdc2 interaction warrants further study, since the
association of EBNA-2 with p34cdc2 may be required to ensure
proper regulation of EBNA-2 function; moreover, the associ-
ation may also affect the function of p34cdc2 similarly to the
effect of the Tax-CDK4 interaction.
All studies of EBNA-2 transactivation of the LMP-1 pro-
moter have been done in asynchronously growing cells when
EBNA-2 was hypophosphorylated (30, 63, 78). Here we report
FIG. 5. Decreased association of PU.1 and EBNA-2 in M-phase-
arrested cells when EBNA-2 is hyperphosphorylated. Immunoprecipi-
tation of EBNA-2 was performed with whole-cell lysates from asyn-
chronously growing (A) and nocodazole-arrested M-phase cells (M). A
portion of the immunoprecipitated lysates was separated on a 10% gel,
and immunoblotting of EBNA-2 and PU.1 was carried out on the same
membrane (top and middle panels). The same samples were separated
on an 8% gel to show more clearly the EBNA-2 hyperphosphorylation
(bottom panel).
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that in M-phase-arrested cells, when EBNA-2 was hyperphos-
phorylated its interaction with PU.1 was suppressed and the
transactivation of the LMP-1 promoter by EBNA-2 decreased
by about 50%. There are numerous examples of protein phos-
phorylation regulating functions of transcription factors or co-
regulators, including modulating protein-protein interactions
(reviewed in reference 80). A well-known example of the in-
fluence of cell-cycle-related phosphorylation on protein asso-
ciation that causes functional change is the Rb protein. Rb
associates with and represses the transactivation ability of E2F,
and the variation of phosphorylation status of Rb during the
cell cycle influences its association with E2F; as a result, E2F-
responsive promoters are regulated during the cell cycle (27,
46). Thus, the decreased association of EBNA-2 with PU.1 in
M phase (Fig. 6), which is likely a result of the conformational
changes caused by hyperphosphorylation (10, 29) of EBNA-2,
might help explain its decreased transactivation of the LMP-1
promoter in M phase. Interestingly, mutation of the PU.1-
binding site in the LMP-1 promoter abolishes approximately
50% of its responsiveness to EBNA-2 (30). It has been re-
FIG. 6. Decreased endogenous LMP-1 mRNA and protein levels in M-phase-arrested cells. (A) RPA was performed on total RNA from
asynchronous (Asy) and M-phase-arrested X50-7 cells (M) with GAPDH and LMP-1 probes (left panel) or GAPDH and EBNA-2 probe (right
panel). Yeast RNA and total RNA from DG75 cells were used as negative controls. A representative result from three independent experiments
is shown. (B) Relative mRNA levels of LMP-1 and EBNA-2 were analyzed by normalizing LMP-1 (left panel) or EBNA-2 mRNA (right panel)
levels to the GAPDH mRNA level with a PhosphorImager. Each data point represents the average of three independent experiments. Error bars
represent the means  standard errors of the means. *, P  0.01. (C) Western blot of LMP-1 from total lysates of asynchronous (Asy) and
M-phase-arrested X50-7 cells (M). -actin levels were used as a loading control.
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ported that purified GST–EBNA-2(310-376) protein can bind
to in vitro-translated PU.1 (30), but attempts to detect the
association by immunoprecipitation with EBNA-2 antibody
were unsuccessful (30). Here, however, we have detected the
association of EBNA-2 with PU.1 by coimmunoprecipitation in
X50-7 cells, providing evidence of an association of these two
proteins in vivo for the first time. Our current ideas about how
EBNA-2 may be hyperphosphorylated in mitosis and the func-
tional consequences are summarized in Fig. 7.
Based on these results, it is tempting to conclude that hypo-
phosphorylated EBNA-2 is active and hyperphosphorylated
EBNA-2 is inactive. So it is then reasonable to expect that in
type III latency cell lines, when EBNA-2 is hyperphosphory-
lated, endogenous LMP-1 mRNA steady-state levels should
decrease, and in fact the LMP-1 mRNA level did decrease in
M phase (Fig. 6). The decreased LMP-1 mRNA level was not
due to decreased EBNA-2 expression, as indicated by the RPA
showing that the EBNA-2 mRNA level did not change in M
phase (Fig. 6). Transcription of all the EBNA genes is driven
by one of two promoters, Cp or Wp, and the activity of these
promoters is mutually exclusive (64, 82, 83). Wp is used during
the initial stages of B-cell immortalization, followed by a switch
to Cp usage (64, 82, 83). In X50-7 cells, in which Cp is deleted
from the EBV genome, all the EBNAs are transcribed from
Wp (84). There is no report that EBNA-2 can transactivate
Wp. Thus, the constant levels of EBNA-2 mRNA suggest that
Wp activity appears not to be affected by hyperphosphorylation
of EBNA-2.
In eukaryotic cells, transcription in mitosis is generally re-
pressed, and this transcriptional repression is thought to be
required for the accurate division of chromosomes at mitosis.
Transcriptional repression in mitosis is regulated at different
levels, among which phosphorylation of a series of transcrip-
tional factors by a mitotic kinase, in most cases involved with
p34cdc2 kinase, is one of the important mechanisms (reviewed
in reference 16). Here we found that EBNA-2, the EBV key
transcriptional transactivator, experiences similar mitosis-spe-
cific phosphorylation that might involve p34cdc2, which is asso-
ciated with its decreased transactivation of the LMP-1 pro-
moter in M phase. Besides the LMP-1 promoter, EBNA-2 can
also transactivate all the other viral promoters, including the
BamHI C (66) and LMP-2A (43) (also called TP1) promoters.
That these promoters are similarly linked to the cell cycle by
hyperphosphorylation of EBNA-2 seems likely, because hyper-
phosphorylation of EBNA-2 might also influence its interac-
tion with RBP-J, which tethers EBNA-2 to Cp and TP1p in a
manner similar to EBNA-2 and PU.1. Hyperphosphorylation
of EBNA-2 might also influence the interaction of EBNA-2
FIG. 7. Mitotic hyperphosphorylation of EBNA-2 and its possible functional consequences. In the interphase, p34cdc2 kinase is inactive due to
the low level of cyclin B1, its regulatory subunit, and phosphorylation of p34cdc2. EBNA-2 is hypophosphorylated in the interphase and
transcriptionally active. Upon entering the M phase of the cell cycle, p34cdc2 kinase becomes activated by accumulation of cyclin B1 and
dephosphorylation of p34cdc2. EBNA-2 is hyperphosphorylated during mitosis by p34cdc2 kinase directly (1) and probably by other kinases as well
(2). Association of EBNA-2 with PU.1 decreases, which may be one of the mechanisms whereby transactivation of the LMP-1 promoter by
EBNA-2 is impaired. In general, the suppression of EBNA-2 transcriptional activity by hyperphosphorylation may repress all the other EBNA-
2-responsive genes during the M phase of the cell cycle.
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with basal transcription factors TFII B (72) and TFII H (70)
and therefore influence transcription in mitosis. It has been
known for decades that the latent EBV episomes are located in
chromosomes (60, 61), and the copy number of EBV episomes
remains essentially constant in each cell line (38). Thus, tran-
scription from the EBV episome may be similarly repressed
during mitosis in type III latency, which might be important for
the accurate division of EBV episomes into daughter cells.
Definitive proof of this hypothesis requires study of other type
III latency gene products in the M phase of the cell cycle and
identification of the phosphorylation sites of EBNA-2; this
work is in progress. In conclusion, our finding that EBNA-2 is
specifically hyperphosphorylated during mitosis allows us to
place the significance of the suppression of EBNA-2 transcrip-
tional function into the general context of the cell in which
mitosis is coupled with repression of general transcriptional
activity.
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